The volume of PET-defined, active bone marrow spared predicts acute hematologic toxicities in anal cancer patients receiving concurrent chemoradiotherapy.

about

The volume of PET-defined, active bone marrow spared predicts acute hematologic toxicities in anal cancer patients receiving concurrent chemoradiotherapy.

Item

http://www.wikidata.org/entity/Q50115535

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The volume of PET-defined, act ...... concurrent chemoradiotherapy.

@en

The volume of PET-defined, act ...... concurrent chemoradiotherapy.

@nl

type

Item

label

The volume of PET-defined, act ...... concurrent chemoradiotherapy.

@en

The volume of PET-defined, act ...... concurrent chemoradiotherapy.

@nl

prefLabel

The volume of PET-defined, act ...... concurrent chemoradiotherapy.

@en

The volume of PET-defined, act ...... concurrent chemoradiotherapy.

@nl

P1476

The volume of PET-defined, act ...... concurrent chemoradiotherapy.

@en

P2093

Christopher Freese

http://www.w3.org/2001/XMLSchema#string

Jordan Kharofa

http://www.w3.org/2001/XMLSchema#string

Luke Lewis

http://www.w3.org/2001/XMLSchema#string

Michael Lamba

http://www.w3.org/2001/XMLSchema#string

Mickaela Sudhoff

http://www.w3.org/2001/XMLSchema#string

P2860

Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.

Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.

Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.

RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal

Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.

Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).

Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal.

Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.

Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients.

P304

1-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/0284186X.2017.1377847

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28903619

http://www.w3.org/2001/XMLSchema#string

P921

chemoradiotherapy